Kyowa Kirin Demonstrates Commitment to Real-world Evidence for POTELIGEO® (mogamulizumab) at EORTC 2023.
TOKYO, September 21, 2023--Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co. Ltd, today announced the acceptance of an extensive programme of data to the annual meeting of the European Organisation for Research and Treatment of Cancer’s Cutaneous Lymphoma Tumour Group (EORTC-CLTG), taking place from the 21st – 23rd of September 2023 in Leiden, the Netherlands.
Source: yahoo.com
